Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron.
Anti-spike protein antibody
BNT162b2
Breakthrough infection
Omicron variant
mRNA-1273
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
03
02
2022
revised:
02
03
2022
accepted:
23
03
2022
pubmed:
11
4
2022
medline:
14
5
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
By December 2021, about 80% of people over the age of 12 had been vaccinated in Japan, and almost all people were vaccinated with the mRNA vaccine. We investigated here the anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. A total of 32 SARS-CoV2 omicron breakthrough infection was included in the study. The median antibody titer at breakthrough infection was 776 AU/mL overall, of which the median antibody titer of BNT162b2 vaccinated was 633 AU/mL and that of mRNA-1273 vaccinated was 9416 AU/mL. This result suggests that low levels of antibody titers 6 months after vaccination do not provide sufficient antibodies to prevent the omicron variant breakthrough infection, which may occur with a higher anti-spike antibody titer after vaccination with mRNA-1273. However, antibody titers in some patients were comparable to those immediately after the second vaccination with either mRNA vaccine.
Identifiants
pubmed: 35397976
pii: S1341-321X(22)00100-3
doi: 10.1016/j.jiac.2022.03.021
pmc: PMC8971116
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Viral
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1015-1017Informations de copyright
Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Lancet Microbe. 2022 Feb;3(2):e81-e82
pubmed: 34901897
J Clin Microbiol. 2021 Aug 18;59(9):e0098921
pubmed: 34165323
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524